Public Records/Experimental Treatment Outcomes

Summary

The bill would make the health information and proprietary pricing details in the Department of Health’s annual report on experimental treatments for terminal or rare diseases confidential and not subject to public‑records requests. It is intended to protect patients’ sensitive medical data and commercial pricing information. The measure did not pass and died in the Health Policy committee.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share